The federal hemp redefinition is six months from changing the cannabinoid market — and the recovery conversation

In November 2025, Congress enacted H.R. 5371 — the omnibus continuing-appropriations package — which substantially amends the Agricultural Marketing Act’s definition of “hemp”. The substantive change is small in word count and large in consequence: the definition shifts from a delta-9 THC concentration standard (the 2018 Farm Bill’s 0.3% benchmark) to a “total THC” standard that includes delta-9, THCA, and “any other cannabinoids that have similar effects” to a tetrahydrocannabinol.

In plain terms, that closes the loophole that has powered most of the post-2018 intoxicating hemp market: products engineered to keep delta-9 below 0.3% while delivering significant intoxication via delta-8, delta-10, THCA conversion, or other minor cannabinoids. Final hemp-derived consumer products are excluded from the legal definition of hemp if they contain more than 0.4 milligrams of total THC. Synthetic cannabinoids are excluded categorically.

The rule takes effect one year after enactment — November 2026.

The market scale being repriced

By 2025, the intoxicating-hemp sector — gas station gummies, smokable THCA flower, delta-8 vape carts, hemp-derived seltzers — was valued at approximately $28.4 billion, supported an estimated 300,000 jobs, and generated roughly $1.5 billion in state tax revenue. The Wyden–Merkley Cannabinoid Safety and Regulation Act, introduced in December, would replace the prohibition with a federal regulatory framework (5 mg per serving, 50 mg per container for edibles, federal age 21, third-party testing). It is not law.

States are not waiting. Ohio enacted SB 56 in December imposing a categorical intoxicating-hemp ban. New Jersey is requiring liquidation of non-compliant inventory on an accelerated timeline. Patchwork compliance is the near-term reality.

Why this matters for people in recovery

For recovery, the practical question is not whether hemp-derived intoxicants are good or bad. It is whether someone with cannabis use disorder who has been buying gummies at a gas station for the last three years — believing what they were doing was fully legal — will have anywhere to go for the conversation that follows when those products disappear from their corner store in November.

The more honest national language about cannabinoids that this rule forces — about THC dose, about non-delta-9 intoxicants, about what is and is not “just CBD” — is overdue. The clinical literature has been clear for some time that cannabinoid hyperemesis syndrome and cannabis use disorder do not respect the legal definition of which molecule put them there. That part of the recovery conversation needs to keep up.

If you are in recovery from cannabis use and the supply you have been using is about to change, it is a reasonable moment to talk to a clinician or a peer about what comes next.

---

If you or someone you love needs help with cannabis use, your state’s 211 line and SAMHSA’s 1-800-662-HELP (4357) line are confidential, free, and available 24/7.